BIO.News Newsletter

A Senate hearing promotes legislation that would provide clarity on patents. Also: heroism and advocacy around arthritis. (670 words, 3 minutes, 21 seconds)

A Most Favored Nation (MFN) pricing agreement was announced—here’s what BIO’s saying about it. Plus, we recap BIO on the American Road in Illinois. (615 words, 3 minutes, 4 seconds)

President Trump announced pharmaceutical tariffs. Also, we continue our series on drug pricing in the U.S. (730 words, 3 minutes, 39 seconds)

The House passed a one-year reauthorization of the SBIR/STTR programs that BIO supports. Also, BIO hits the road in Texas. (730 words, 3 minutes, 39 seconds)

We look at why access to innovation matters and the need to put international prices in perspective. (707 words, 3 minutes, 32 seconds)

Welcome back. Today, we have a look at what BIO's saying about superbugs (and how to combat them), profiles of the BIO 2025 Start-Up Stadium winners, and more news you need to know. (733 words, 3 minutes, 39 seconds)

As summer comes to a close, we look at two of BIO’s big priorities when Congress returns in September. We have the facts, plus more news to know before the holiday weekend. (735 words, 3 minutes, 40 seconds)We’ll take a quick break for Labor Day, and resume publication on Monday, September 8.

We look back at BIO 2025 discussions on GLP-1s, women's health, and psychedelics – and look ahead at what a new study tells us about the future of cervical cancer. (645 words, 3 minutes, 13 seconds)

HHS is pulling mRNA research funding – here's what BIO says about it, plus a look at what drives people to become patient advocates. (674 words, 3 minutes, 22 seconds)

Here's what you need to know about the U.S.-EU tariff deal’s impact on the U.S. pharmaceutical industry—plus, BIO’s work to reauthorize the SBIR/STTR programs. (801 words, 4 minutes)